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CC BY-NC-ND license (http://creativeAbstract The lower limits of virus detection of hepatitis C virus (HCV) RNA detection assays
are continuously improving. We aimed to assess the utility of more precise definition of 4th
week viral load [rapid virological response (RVR)] in predicting sustained virological response
(SVR) in HCV genotype 1 patients treated with pegylated-interferon (PEG-IFN) and ribavirin.
Clinical data of treatment-naı¨ve HCV genotype 1 patients were retrospectively collected from
2009 to 2014. Patients were grouped according to 4th week viral load as follows: undetectable
(nZ 90) and detectable but not quantifiable (< 12 IU/mL, nZ 27). All patients received PEG-
IFNa-2a or -2b and ribavirin for 24 weeks. Serum HCV RNA levels were measured by Abbott Re-
alTime (ART; Abbott Molecular, Abbott Park, IL, USA) HCV assay. SVR was 95.5% and 63% in the
undetectable group and < 12 IU/mL group of 4th week viral load, respectively. The between-
group difference in SVR was significant (p < 0.001). We determined 4th week viral load was
independently associated with SVR (odds ratio Z 19.28; p Z 0.002) and a good predictor of
SVR [area under the curve (AUC)Z 0.775; pZ 0.001]. ART HCV assays had a stronger SVR pre-
dictive value in HCV genotype 1 patients, indicating that only the undetectable group of 4th
week viral load patients measured by ART HCV assay should be considered for shorter treat-
ment time (24 weeks) with PEG-IFN and ribavirin.eclare no conflicts of interests.
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Although direct-acting antivirals developed in Western
countries have recently been licensed in the AsiaePacific
region, pegylated-interferon (PEG-IFN) and ribavirin com-
bination therapy remains the standard of care for chronic
hepatitis C in Asian populations [1]. The treatment duration
for chronic hepatitis C is 48 weeks for genotypes 1 or
4 weeks and 24 weeks for genotypes 2 or 3, respectively.
Previous studies have demonstrated that shorter treatment
periods (24 weeks) for hepatitis C virus (HCV) genotype 1
can be considered in patients who achieve a rapid virolog-
ical response (RVR) at 4 weeks of therapy, particularly
those with low baseline viral loads [2e4].
According to the European Association for the Study of
the Liver (EASL) guidelines in 2011, the RVR definition for
HCV consists of HCV RNA virus levels < 50 IU/mL, and the
same recommendation was noted in the Asian Pacific As-
sociation for the Study of the Liver consensus in 2012 [1,5].
The techniques used for HCV virus detection have recently
improved, and new EASL guidelines in 2014 defined RVR for
HCV as < 15 IU/mL [6]. Several studies have evaluated
different HCV RNA detection assays to determine if the
increased sensitivity of the lower limit of detection (LLOD)
of different assays has more impact on clinical treatment.
Two new assays, COBAS Ampliprep/COBAS TaqMan (CAP/
CTM; Roche Molecular Systems, Pleasanton, CA, USA) HCV
Test version 2.0 (LLOD, 15 IU/mL) and Abbott RealTime
(ART; Abbott Molecular, Abbott Park, IL, USA) HCV (LLOD,
12 IU/mL), that are commonly used in clinical practice
reportedly have similar sensitivities [7].
Although the previous RVR definition for HCV RNA levels
was < 50 IU/mL, the updated definition is based on higher
sensitivity assays and is set at RNA levels between 12 IU/mL
and 15 IU/mL. This improvement in HCV RNA assays has
allowed the categorization of patients with RVR (4th week
viral load) < 50 IU/mL into three groups: detectable and
quantifiable (50e12 IU/mL or 15 IU/mL), detectable but not
quantifiable (< 12 IU/mL or 15 IU/mL) and undetectable
(target not detected) [8]. However, the utility of newer
assays in predicting the treatment response of shorter
therapy in patients with HCV genotype 1 remains unknown.
Therefore, the present study aimed to assess if the
different 4th week viral load definition used by ART HCV
assay can predict sustained virological response (SVR) in
patients with HCV genotype 1, who were treated with PEG-
IFN and ribavirin.Methods
Patient selection
We have used ART HCV assays for the quantification of HCV
RNA at our institution since 2009. Therefore, we performeda single-center retrospective study of ART HCV assay data
collected from 2009 to 2014 at our hospital. All patients
fulfilled the treatment criteria of the National Health In-
surance (NHI) of Taiwan including: (1) positive serum anti-
HCV antibody; (2) the detection of HCV RNA in serum; (3)
treatment-naı¨ve; and (4) abnormal alanine transaminase
levels  40 IU/L (upper limit). Patients were aged
20e75 years. In addition, once RVR was achieved (HCV viral
load) at 4th week, patients received shorter treatment
(24 weeks), regardless of the baseline viral load according
to the NHI criteria. A total of 315 patients with HCV geno-
type 1 infection were initially analyzed and divided into
four groups according to the 4th week HCV RNA level as
follows: (1) 141 patients with HCV RNA > 50 IU/mL; (2) 36
patients with HCV RNA between 12 IU/mL and 50 IU/mL; (3)
48 patients with HCV RNA detectable but unquantifiable (<
12 IU/mL); and (4) 90 patients with undetectable HCV RNA
(target not detected). In the 4th week viral load (< 12 IU/
mL but detectable) group, 27 patients received 24 weeks of
treatment and 21 patients received 48 weeks of treatment
under the judgment of different clinicians. In the group of
patients with undetectable HCV RNA, all patients received
24 weeks of treatment. Therefore, data was only collected
from patients whose 4th week viral load was < 12 IU/mL or
undetectable and who received the shorter treatment
(24 weeks).
The treatment regimens consisted of PEG-IFN and
weight-based doses of ribavirin (Rebetol; MSD, Las Piedras,
Puerto Rico; 1000 mg/d for body weight  75 kg and
1200 mg/d for body weight > 75 kg) combined therapy.
PEG-IFN included PEG-IFNa-2a (40KD; PEGSYS; Roche,
Basel, Switzerland; 180 mg/wk) and PEG-IFNa-2b (PEG-
Intron; MSD, Cork, Ireland; 1.5 mg/kg/wk). The “80/80/80
rule” was defined as > 80% adherence to the total dose of
PEG-IFN and ribavirin, taking > 80% of the required dosage
of one or both drugs, for > 80% of the expected duration of
treatment. The study was approved by the Changhua
Christian Hospital’s Ethics Committee, Changhua, Taiwan
(No. 140809).
Assessments and endpoints
We used ART HCV assays (RealTime HCV and HCV Genotype
II, Abbott Molecular) to quantitatively measure HCV RNA
concentrations and genotyping. Samples were tested on the
platform, as described in the manufacturer’s instructions.
Results were categorized as undetectable, < 12 IU/mL,
12 IU/mLe8.0 log10 IU/mL, and > 8.0 log10 IU/mL. SVR was
defined as serum HCV RNA levels that remained undetect-
able 24 weeks after the end of the combined therapy.
Statistical analyses
The characteristics of patients with undetectable and <
12 IU/mL of 4th week viral load are presented as numbers of
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compare characteristics between different groups of 4th
week viral load, the Chi-square test was used to analyze
categorical variables, and the Student t test was used to
analyze continuous variables. Univariate and multivariate
logistic regression analyses were used to evaluate the ef-
fects and significance of SVR variables. A backward elimi-
nation procedure was performed to select potential
predictors. Receiver operator characteristic curves were
constructed to assess the predictive accuracy of 4th week
viral load for SVR. Area under the curve (AUC) values for
predicting SVR with 4th week viral load were calculated.
Statistical analyses were performed using SPSS version 18.0
(SPSS Inc., Chicago, IL, USA). A p value (two-tailed) of <
0.05 was considered statistically significant.
Results
We collected clinical data from 117 patients with unde-
tectable and < 12 IU/mL of 4th week viral load, who
completed a shorter treatment of 24 weeks. The unde-
tectable individuals of 4th week viral load group comprised
90 patients and the 4th week viral load < 12 IU/mL group
comprised 27 patients. Baseline clinical data, including
age, gender, body mass index (BMI), alanine aminotrans-
ferase (ALT), HCV genotype, baseline viral loads, PEG-IFN
type, mean ribavirin dosage, 80/80/80 rule, cirrhosis, and
type 2 diabetes mellitus status are summarized in Table 1.
No statistically significant difference in age, gender, BMI,
ALT, PEG-IFN type, mean ribavirin dosage, or cirrhosisTable 1 Patient characteristics at baseline.
Characteristics 4th wk
viral load
(Undetectable)
4th wk
viral load
(< 12 IU/mL)
p
N 90 27
Age (y) 52.9  11.9 56.1  12 0.224
Male gender 64 (71) 20 (74) 0.764
BMI 24.3  3.2 24.5  2 0.713
ALT 130.9  164.6 104.1  70.4 0.414
Genotype Ia/Ib 12/78 1/26 0.163
Baseline HCV
RNA level
(log IU/mL)
5.09  1.03 5.86  0.61 < 0.001
Baseline HCV
RNA level
(< 800,000 IU/mL)
66 (73) 13 (48) 0.014
Baseline HCV
RNA level
(< 400,000 IU/mL)
62 (69) 10 (37) 0.003
PEG-IFN a-2a/2b 66/24 19/8 0.762
Mean RBV dose (g) 161.4  35.4 227.4  321.7 0.297
80/80/80 rule 70 (78) 26 (96) 0.028
Cirrhosis 16 (18) 7 (26) 0.35
Type 2 DM 18 (20) 1 (4) 0.044
Data are presented as n (%) or mean  standard deviation.
ALT Z alanine aminotransferase; BMI Z body mass index;
DM Z diabetes mellitus; HCV Z hepatitis C virus;
PEG-IFN Z pegylated-interferon; RBV Z ribavirin.status was observed between the two groups; however, a
lower baseline viral load and 80/80/80 rule were observed
in the undetectable of 4th week viral load group, and higher
type 2 diabetes mellitus status in the group of < 12 IU/mL.
Mean baseline viral loads were 5.09 ( 1.03) and 5.86 (
0.61) log10 IU/mL in the undetectable and < 12 IU/mL of 4
th
week viral load, respectively.
SVRs were 95.5% and 63% in the undetectable and <
12 IU/mL of 4th week viral load, respectively. Moreover, a
statistically significant difference in SVR was observed be-
tween the two groups (Figure 1).
The results of univariate and multivariate analyses are
summarized in Table 2. Univariate logistic regression iden-
tified undetectable and < 12 IU/mL of 4th week viral load
and high baseline HCV RNA levels (> 400,000 IU/mL
or > 800,000 IU/mL) as statistically significant predictors of
SVR [odds ratio (OR) Z 12.65; p < 0.001 for 4th week viral
load; OR Z 0.30; p Z 0.042 for high HCV RNA levels at
baseline]. Multivariate logistic regression demonstrated
only 4th week viral load as a statistically significant pre-
dictor of SVR. After performing the backward elimination
procedure, 4th week viral load remained as a significant
independent predictor of SVR (ORZ 19.28; pZ 0.002). The
same results are also found in patients with baseline low
viral load (< 400,000 IU/mL), therefore 4th week viral load
is still a statistically significant predictor of SVR (Table 3).
The AUC of the 4th week viral load as a predictor of SVR was
0.775 [95% confidence interval (CI) Z 0.630e0.919;
p Z 0.001; Figure 2], indicating good predictive utility for
SVR.Discussion
To the best of our knowledge, the present study is the first
study to examine 4th week viral load (RVR) according to the
new definitions (< 12 IU/mL or undetectable), using ART
HCV assay to predict SVR in patients with HCV genotype 1
receiving the short-term 24-week treatment. The overall
SVR was 88% in patients with 4th week viral load < 12 IU/mL
(including both < 12 IU/mL and undetectable groups), who
received the 24-week treatment in our study. However,
further division of the 4th week viral load group into two
additional groups demonstrated SVRs of 63% and 95.5% in
the 4th week viral load < 12 IU/mL and undetectable 4th
week viral load, respectively.
HCV RNA levels can be detected using two main target
amplification methods, real-time polymerase chain reac-
tion (PCR) and transcription-mediated amplification [9].
Currently, PCR is the most popular method [10e13]. The
LLOD and lower limit of quantification have been continu-
ously improving with the development of new primers,
probes, and protocols for PCR. A recent study highlighted
that in patients receiving telaprevir or boceprevir with PEG-
IFN/ribavirin triple therapy, SVR can be more precisely
predicted in patients with undetectable HCV RNA than in
those with detectable but not quantifiable HCV RNA.
Further, a difference of 20% in SVR between two distinctly
defined RVR groups has been reported [14]. Therefore,
there is a clinical need to evaluate the new HCV RNA
detection assays in conjunction with currently used treat-
ment regimens.
Figure 1. SVR rates of the patients with undetectable and < 12 IU/mL at 4th week after treatment according to the high and low
baseline viral load ( 400,000 IU/mL or > 400,000 IU/mL). HCV Z hepatitis C virus; SVR Z sustained virological response.
Table 2 Predictors of sustained virological response.
Variables Univariate logistic
regression
Multivariate logistic
regressiona
Multivariate logistic
regressionb
Multivariate logistic
regressionc
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p
Age 0.98 (0.93, 1.03) 0.476 0.99 (0.92, 1.07) 0.831 0.99 (0.92, 1.06) 0.720 0.99 (0.91, 1.06) 0.695
Male gender 0.39 (0.08, 1.83) 0.232 0.26 (0.04, 1.70) 0.161 0.28 (0.05, 1.76) 0.176 0.22 (0.03, 1.51) 0.126
BMI 0.98 (0.81, 1.18) 0.794 0.89 (0.67, 1.19) 0.430 0.88 (0.66, 1.18) 0.388 0.88 (0.66, 1.18) 0.388
ALT 1.00 (1.00, 1.01) 0.563 1.00 (0.99, 1.01) 0.896 1.00 (0.99, 1.01) 0.878 1.00 (0.99, 1.01) 0.884
Genotype Ia/Ib 0.71 (0.14, 3.63) 0.688 0.12 (0.01, 1.32) 0.083 0.13 (0.11, 1.44) 0.095 0.13 (0.11, 1.42) 0.094
Baseline HCV
RNA level
(log IU/mL)
0.58 (0.31, 1.08) 0.087 0.852 (0.33, 2.22) 0.743 d d d d
Baseline HCV
RNA level
(> 800,000
IU/mL, n)
0.31 (0.1, 0.96) 0.043 d d 0.46 (0.11, 1.91) 0.284 d d
Baseline HCV
RNA level
(> 400,000
IU/mL)
0.30 (0.09, 0.96) 0.042 d d d d 0.44 (0.09, 2.10) 0.305
PEG-IFN a-2a/2b 0.70 (0.18, 2.68) 0.598 0.40 (0.07, 2.23) 0.295 0.43 (0.08, 2.48) 0.347 0.49 (0.08, 2.88) 0.426
Mean RBV
dose (g)
1.00 (0.99, 1.01) 0.753 1.02 (0.99, 1.06) 0.211 1.02 (0.99, 1.06) 0.179 1.03 (0.99, 1.06) 0.165
80/80/80 rule 3.20 (0.04, 2.59) 0.285 0.25 (0.01, 5.80) 0.390 0.21 (0.01, 4.91) 0.333 0.22 (0.01, 5.08) 0.347
Cirrhosis 0.57 (0.16, 2) 0.376 0.83 (0.16, 4.16) 0.815 0.94 (0.18, 4.88) 0.942 0.94 (0.18, 4.94) 0.942
Type 2 DM 1.19 (0.24, 5.79) 0.833 0.46 (0.06, 3.90) 0.479 0.47 (0.06, 3.72) 0.470 0.55 (0.07, 4.64) 0.584
4th wk viral load 12.65
(3.55, 45.08)
< 0.001 22.41
(3.34, 150.61)
0.001 21.61
(3.42, 136.50)
0.001 19.28
(3.03, 122.49)
0.002
ALT Z alanine aminotransferase; BMI Z body mass index; CI Z confidence interval; DM Z diabetes mellitus; HCV Z hepatitis C virus;
OR Z odds ratio; PEG-IFN Z pegylated-interferon; RBV Z ribavirin.
a Multivariate analysis adjusted for age, gender, BMI, ALT, genotype, baseline HCV RNA level (log IU/mL), PEG-IFN, mean RBV dose,
80/80/80 rule, cirrhosis, DM, and 4th week viral load.
b Multivariate analysis adjusted for age, gender, BMI, ALT, genotype, baseline HCV RNA level (> 800,000 IU/mL), PEG-IFN, mean RBV
dose, 80/80/80 rule, cirrhosis, DM, and 4th week viral load.
c Multivariate analysis adjusted for age, gender, BMI, ALT, genotype, baseline HCV RNA level (> 400,000 IU/mL), PEG-IFN, mean RBV
dose, 80/80/80 rule, cirrhosis, DM, and 4th week viral load.
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Table 3 Predictors of sustained virological response in patients with baseline HCV RNA level < 400,000 IU/mL (n Z 72).
Variables Univariate logistic regression Multivariate logistic regression
OR (95% CI) p OR (95% CI) p
Age 0.96 (0.93, 1.08) 0.234 1.11 (0.94, 1.30) 0.241
Male gender 0.59 (0.06, 5.59) 0.644 3.39 (0.04, 277.09) 0.587
BMI 1.04 (0.79, 1.42) 0.815 1.54 (0.53, 4.43) 0.425
ALT 1.00 (0.99, 1.01) 0.946 1.00 (0.98, 1.02) 0.702
Baseline HCV RNA level (log IU/mL) 0.42 (0.08, 2.36) 0.327 0.46 (0.01, 16.05) 0.669
PEG-IFN a-2a/2b 0.51 (0.05, 4.85) 0.559 0.06 (0.00, 4.40) 0.196
Mean RBV dose (g) 1.01 (0.98, 1.03) 0.700 1.03 (0.98, 1.09) 0.263
Cirrhosis 1.06 (0.11, 10.22) 0.962 0.81 (0.01, 48.89) 0.919
4th wk viral load 40.67 (3.89, 424.83) 0.002 823.46 (2.51, 270188.36) 0.025
ALT Z alanine aminotransferase; BMI Z body mass index; CI Z confidence interval; HCV Z hepatitis C virus; OR Z odds ratio;
PEG-IFN Z pegylated-interferon; RBV Z ribavirin.
Figure 2. ROC curves for 4th week viral load (RVR) as a
predictor of SVR. The AUC for RVR as a predictor of SVR was
0.775 (95% confidence interval, 0.630e0.919; p Z 0.001).
AUC Z area under the curves; CI Z confidence interval;
ROC Z receiver-operating characteristic; RVR Z rapid viro-
logical response; SVR Z sustained virological response.
Abbott RealTime assay for hepatitis C patients 385Novel methods for quantifying HCV RNA include two
major assays, CAP/CTM HCV Test version 2.0 and ART HCV
assays [9]. Individual assays differ in LLOD (CAP/CTM
version 2.0Z 15 IU/mL; ARTZ 12 IU/mL) and assay design
[7,15,16]. A recent study by Peiffer et al. [17] used both
assays to analyze 4th week viral load status in patients with
HCV receiving dual combination and triple therapy (the
INDIV-2 study). They observed a 35% difference in 4th week
viral load status between the two assays, with fewer pa-
tients regrouped as “undetectable” from the “detectable
but unquantifiable” group using the ART assay. However,further studies are required to identify patients likely to
benefit from shorter treatment [17].
The study by Sarrazin et al. [18] analyzed 962 patients
who received HCV PEG-IFN a-2a/ribavirin combination
therapy using the CAP/CTM HCV assay. Patients with ge-
notype 1 who received 24 weeks of short-term treatment
and those with genotype 2 or 3 who received 16 weeks of
short-term treatment were divided into the following
groups based on 4th week viral load status: 4th week viral
load < 50 IU/mL, 4th week viral load < 15 IU/mL, and
undetectable 4th week viral load. The results of their
study demonstrated similar SVR in each of the three 4th
week viral load groups [18]. However, this study only
included 21 patients with genotype 1 who had RVR and
received 24 weeks of short-term treatment. Eighteen of
the 21 patients had undetectable 4th week viral load, and
the remaining three were in the undetectable 4th week
viral load plus detectable < 15 IU/mL group. Moreover, a
very small number of patients with genotype 1 were
included. Another study by Vermehren et al. [19] analyzed
patients with HCV genotype 1, including 169 patients
receiving dual therapy and 164 patients receiving
telaprevir-based triple therapy. HCV RNA levels in all pa-
tient samples were detected by CAP/CTM and ART. RVR
statuses of fewer patients were determined to be unde-
tectable by ART compared with those analyzed by CAP/
CTM (9% vs. 16%) in treatment-naı¨ve groups receiving dual
therapy. In total, 27 patients received 24 weeks of short-
term treatment, including 11 patients who had detectable
4th week viral load < 12 IU/mL, as determined by ART. No
cases of treatment relapse were observed at 24 weeks
follow-up. The authors concluded that for ART, 4th week
viral load < 12 IU/mL could be a valuable predictive factor
for short-term treatment regimens [19]. In addition, a
small number of patients were included in this study, and
patients were included from three centers. Although the
present study was retrospective in nature, we included
117 patients who were all HCV genotype 1 positive and
had received 24 weeks of short-term treatment. Twenty-
seven of the 117 patients had 4th week viral load <
12 IU/mL detected by ART. Therefore, we were able to
demonstrate a statistically significant difference between
the undetectable 4th week viral load and 4th week viral
load < 12 IU/mL groups.
386 P.-y. Su et al.Previous studies have demonstrated that treatment
regimens for HCV genotype 1 can be shortened to 24 weeks
in certain situations, such as in patients with lower baseline
viral loads [2,3,20,21]. However, there is a lack of
consensus regarding criteria used to define the upper limit
of low viral load at baseline [4]. The results of the present
study indicate that exact 4th week viral load status and low
viral load at baseline are important predictors of SVR. In
particular, 4th week viral load status was found to be more
significantly associated with SVR; however, age, cirrhosis,
and baseline viral load were not.
There were some limitations to the present study. First,
this was a retrospective study in which a small number of
patients were analyzed. Second, all patients in the present
study received 24 weeks of short-term therapy once they
had achieved RVR at 4 weeks, regardless of baseline viral
load. This approach was followed according to regional
practice guidelines set in Taiwan. Third, the baseline viral
load in the undetectable 4th week viral load group was
lower than that in the 4th week viral load < 12 IU/mL group.
However, 4th week viral load status remained a strong
predictor of SVR following multivariate analysis.
In conclusion, undetectable 4th week viral load
measured using ART HCV assay was a strong predictor of
SVR in patients with HCV genotype 1 receiving a 24-week
short-term treatment. Exact 4th week viral load has utility
in identifying patients in whom short-term treatment pe-
riods would be inadequate, thereby potentially preventing
treatment failure. Only patients with undetectable 4th
week viral load by ART HCV assay should be considered for
shortened treatment schedules. However, large random-
ized studies are required to validate the findings of the
present study.
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